Sign In
Buy MYGN
$4.50
-0.0400 (-0.88%)
At Close: Jun 22, 2026
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
09:05am, Tuesday, 23'rd Jun 2026
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
11:05am, Tuesday, 09'th Jun 2026
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 04'th Jun 2026
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
01:10pm, Tuesday, 02'nd Jun 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
09:05am, Tuesday, 02'nd Jun 2026
SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa a
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
10:26am, Thursday, 28'th May 2026
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
10:21am, Thursday, 28'th May 2026
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
09:53am, Wednesday, 27'th May 2026
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
09:05am, Wednesday, 27'th May 2026
SALT LAKE CITY, May 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces it will share data demonstrating the
SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)
10:35am, Monday, 18'th May 2026
Myriad (MYGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
11:00am, Friday, 15'th May 2026
SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress Jac
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
04:05pm, Thursday, 07'th May 2026
SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participa
Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript
11:31pm, Tuesday, 05'th May 2026
Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
09:31pm, Tuesday, 05'th May 2026
Myriad Genetics (MYGN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.03 per share a year ago.
